DrugPatentWatch Database Preview
DESONATE Drug Profile
When do Desonate patents expire, and what generic alternatives are available?
Desonate is a drug marketed by Leo Pharma As and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.
This drug has thirty-four patent family members in twenty-two countries.
The generic ingredient in DESONATE is desonide. There are thirty drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the desonide profile page.
Summary for DESONATE
| International Patents: | 34 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 44 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,102 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for DESONATE |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DESONATE |
| DailyMed Link: | DESONATE at DailyMed |
Pharmacology for DESONATE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Medical Subject Heading (MeSH) Categories for DESONATE
Synonyms for DESONATE
| (11ss,16alpha)-11,21-Dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione |
| (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0;{2,9}.0;{4,8}.0;{13,18}]icosa-14,17-dien-16-one |
| (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one |
| 11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone |
| 11beta,21-dihydroxy-16alpha,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione |
| 11beta,21-dihydroxy-16alpha,17-isopropylidenedioxypregna-1,4-diene-3,20-dione |
| 11beta,21-dihydroxy-16alpha,17alpha-isopropylidenedioxypregna-1,4-diene-3,20-dione |
| 16-alpha-Hydroxyprednisole-16,17-acetonide |
| 16?,17-[1-Methylethylidenebis(oxy)]-11?,21-dihydroxypregna-1,4-diene-3,20-dione |
| 16alpha-hydroxyprednisole-16,17-acetonide |
| 16alpha-hydroxyprednisolone-16alpha,17-acetonide |
| 16alpha,17-[1-Methylethylidenebis(oxy)]-11beta,21-dihydroxypregna-1,4-diene-3,20-dione (Desonide) |
| 16alpha,17alpha-isopropylidenedioxyprednisolone |
| 638-94-8 |
| 638D948 |
| AB01274712_02 |
| AB01274712-01 |
| AB2000229 |
| Apolar |
| AS-13892 |
| budesonide acetonide |
| C-22009 |
| CAS-638-94-8 |
| CC-26356 |
| CCG-221279 |
| CHEBI:204734 |
| CHEMBL1201109 |
| CS-2228 |
| D 2083 |
| D-2083 |
| D02JNM |
| D03696 |
| D2083 |
| DB01260 |
| desfluorotriamcinolone acetonide |
| Desilux |
| Desonida |
| Desonida [INN-Spanish] |
| DESONIDE |
| Desonide (USAN/INN) |
| Desonide [USAN:INN:BAN] |
| Desonidum |
| Desonidum [INN-Latin] |
| DesOwen |
| Desowen (TN) |
| DSSTox_CID_26756 |
| DSSTox_GSID_46756 |
| DSSTox_RID_81880 |
| DTXSID7046756 |
| EINECS 211-351-6 |
| Flusemidon |
| GTPL7066 |
| Hamiltoderm |
| HY-B0248 |
| J280872D1O |
| K016 |
| Locapred |
| Locapred, Topifug, Tridesilon, Desonide |
| Locapred;Topifug;Tridesilon |
| MolPort-003-987-087 |
| NCGC00167983-01 |
| NCGC00274065-01 |
| Prednacinolone |
| Prednisolone-16,17-acetonide, 16-alpha-hydroxy- |
| Pregna-1,4-diene-3,20-dione, 11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (11beta,16alpha)- |
| Prenacid |
| Q-101382 |
| Reticus |
| s1701 |
| SC-17104 |
| SCHEMBL3631 |
| Sterax |
| Steroderm |
| TL8004516 |
| Topifug |
| Tox21_112603 |
| Tox21_112603_1 |
| Tridesilon |
| Tridesonit |
| UNII-J280872D1O |
| Verdeso |
| Verdeso (TN) |
| Verdeso Foam (TN) |
| WBGKWQHBNHJJPZ-LECWWXJVSA-N |
| ZINC4212851 |
| Zotinar |
US Patents and Regulatory Information for DESONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Leo Pharma As | DESONATE | desonide | GEL;TOPICAL | 021844-001 | Oct 20, 2006 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for DESONATE
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | Gel | 0.05% | ➤ Subscribe | ➤ Sign Up |
International Patents for DESONATE
Supplementary Protection Certificates for DESONATE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 13/044 | Ireland | ➤ Sign Up | PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322 |
| 1304992/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014 |
| 2013025,C1304992 | Lithuania | ➤ Sign Up | PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323 |
| 2013 00053 | Denmark | ➤ Sign Up | PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
